

ISO 17822:2020 (E)

In vitro diagnostic test systems — Nucleic acid amplification-based examination procedures for detection and identification of microbial pathogens - Laboratory quality practice guide

Contents

	Foreword
	Introduction
1	Scope
2	Normative references
3	Terms and definitions
4	General laboratory requirement for microbial pathogens NAAT
4.1	General laboratory risk management and biosafety requirements
4.2	General laboratory set ups for pathogen detection
4.3	Commercial equipment (including software programs)
4.4	Laboratory personnel
5	Planning and implementation of pathogen NAAT assay
5.1	Quality control material
5.1.1	Examination of quality control material
5.1.2	Defining target sequence
5.2	Verification and validation
6	Verification or validation of test systems
6.1	Predicate assay selection by method comparison
7	Assay design and development of LDT
7.1	General
7.1.1	Definition of customer/patient's and stakeholder needs of the intended use of the assay
7.1.2	General criteria for Verification of assay
7.1.3	Specific criteria for verification of assay design input specifications
7.1.4	Validation of intended use
7.2	Diagnostic workflow analysis for Nucleic NAAT procedure
7.2.1	Pre-analytical workflow requirements
7.2.2	Analytical workflow requirements
7.2.3	Post-analytical workflow requirements
7.3	Verification and validation performance characteristics
7.3.1	Range of detection
7.3.2	Test accuracy (Trueness and Precision)
7.3.2.1	Trueness studies
7.3.2.2	Precision studies
7.4	Analytical sensitivity / limit of detection
7.4.1	Validation of assay
7.4.1.1	Validation of study report
7.4.1.2	Partial Validation
8	Implementation and use in the laboratory
9	Reporting and interpretation of results
10	Quality assurance procedures
10.1	Performance monitoring and optimization of the assay
10.2	Inter-laboratory comparison

Annex A (informative) Pre-analytical consideration for sample preparation

- A.1 Serum and plasma**
 - A.1.1 Sample collection**
 - A.1.2 Sample storage and transport**
 - A.1.3 Controlling for interfering substances**
- A.2 Urine**
 - A.2.1 Sample collection**
 - A.2.2 Sample storage and transport**
 - A.2.3 Sample preparation**
- A.3 Sputum**
 - A.3.1 Sample collection**
 - A.3.2 Sample storage and transport**
 - A.3.3 Sample preparation**
- A.4 Whole blood and bone marrow**
 - A.4.1 Sample Collection**
 - A.4.2 Sample storage and transport**
 - A.4.3 Sample preparation**
- A.5 Pleural effusion, ascites, pericardial fluid, pancreatic fluid and Broncho-Alveolar Lavage (BAL) fluid**
 - A.5.1 Sample Collection**
 - A.5.2 Sample storage and transport**
 - A.5.3 Sample preparation**
- A.6 Lymph nodes and solid tissues (biopsy or surgery)**
 - A.6.1 Sample Collection**
 - A.6.2 Sample storage and transport**
 - A.6.3 Sample preparation**
- A.7 Stool**
 - A.7.1 Sample Collection**
 - A.7.2 Sample storage and transport**
 - A.7.3 Sample preparation**

Annex B (informative) Verification and validation of assays

Page count: 39